EULAR SSc Recommendations Now Include Immunosuppressants : v

The update to 2017 recommendations include targeted synthetic and biologic disease-modifying antirheumatic drugs for the first time.

Related Keywords

Milan , Lombardia , Italy , Ariane Herrick , European Alliance Of Associations , European Congress , Astrazeneca , Mitsubishi , University Of Manchester England , Glaxosmithkline , Boehringer Ingelheim , European Alliance , Del Galdo , Leeds Teaching Hospital , Scleroderma Trials , Scleroderma , Crest Syndrome , Biologic Therapy , Pulmonary Hypertension , Systemic Sclerosis , Diffuse Scleroderma , Interstitial Lung Disease , Lung , Heart Failure , Lung Fibrosis , Pulmonary Fibrosis , Ibrosis Pulmonary , Monoclonal Antibody , Etuximab , Ituximab , Hypertension , Antineoplastic Drug , Nti Cancer Agents , Evacizumab , Rlotinib , Efitinib , Matinib , U11248 , Unitinib , Rastuzumab , Europe ,